Institute of Clinical Immunology Center, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Department of Internal Medicine, the First Affiliated Hospital of Harbin Medical University, Harbin, China.
J Leukoc Biol. 2021 Feb;109(2):415-424. doi: 10.1002/JLB.5MR0420-008RR. Epub 2020 Sep 23.
Rheumatoid arthritis (RA) is a chronic inflammatory condition characterized by articular synovitis that eventually leads to the destruction of cartilage and bone in the joints with resulting pain and disability. The current therapies for RA are divided into 4 categories: non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, nonbiological disease-modifying anti-rheumatic drugs (DMARDs), and biological DMARDs. Each drug grouping is beset with significant setbacks that not only include limited drug bioavailability and high clearance, but also varying degrees of drug toxicity to normal tissues. Recently, nanotechnology has provided a promising tool for the development of novel therapeutic and diagnostic systems in the area of malignant and inflammatory diseases. Among these, magnetic nanoparticles (MNPs) have provided an attractive carrier option for delivery of therapeutic agents. Armed with an extra magnetic probe, MNPs are capable of more accurately targeting the local lesion with avoidance of unpleasant systemic side effects. This review aims to provide an introduction to the applications of magnetic nanoparticles in RA, focusing on the latest advances, challenges, and opportunities for future development.
类风湿关节炎（RA）是一种慢性炎症性疾病，其特征为关节滑膜炎，最终导致关节软骨和骨破坏，引起疼痛和残疾。目前 RA 的治疗方法分为 4 类：非甾体抗炎药（NSAIDs）、糖皮质激素、非生物性疾病修饰抗风湿药（DMARDs）和生物 DMARDs。每个药物类别都存在重大的缺陷，不仅包括药物生物利用度有限和清除率高，而且还存在不同程度的药物对正常组织的毒性。最近，纳米技术为恶性和炎症性疾病领域的新型治疗和诊断系统的发展提供了一个有前途的工具。在这些方法中，磁性纳米颗粒（MNPs）为输送治疗剂提供了有吸引力的载体选择。MNPs 配备了额外的磁性探针，能够更准确地靶向局部病变，避免不愉快的全身副作用。本综述旨在介绍磁性纳米颗粒在 RA 中的应用，重点介绍最新进展、挑战和未来发展的机遇。
